Drug class
Uricosuric agent; non-purine xanthine oxidase inhibitor
Mechanism of action
Lowers serum urate through uricosuric activity by reducing renal tubular urate reabsorption; published pharmacology also describes non-purine xanthine oxidase inhibition. The relative contribution of each action depends on the source and product.
General use cases
- Treatment of chronic hyperuricaemia and gout in selected patients where authorised, generally when first-line urate-lowering therapy is unsuitable or ineffective. It is not for treatment of an acute gout attack. Use is limited in many jurisdictions because of serious hepatotoxicity, including reports of fatal liver injury.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
